Mundipharma and Purdue reach new deal to in-licence product from Esteve

Mundipharma and its independent associated company, USA-based Purdue Pharma, today announced that, following completion of Phase II studies, they have exercised their option and taken over full responsibility from Spain’s Laboratorios Esteve for the clinical, regulatory and commercial development of a potential first-in-class sigma-1 antagonist(S1A or MR309/E-52862).

Mundipharma and Esteve recognize that the problem of pain is not solved and are committed to developing new treatments to help patients better manage their pain. The addition of this asset to the Mundipharma pain pipeline continues the growth of the global pain franchise, an area of deep heritage and experience for the Mundipharma network of independent associated companies worldwide.

MR309/E-52862 is a potent and highly selective sigma-1 antagonist that may provide a new way to approach the management of neuropathic pain, one of the most challenging pain conditions to manage.